



Media Advisory

For Immediate Release

AI and liver disease detection and faecal microbiota transplants to treat advanced cirrhosis among the scientific highlights of Europe’s biggest liver disease gathering in Vienna

The impact of the Russian invasion on Ukraine’s hepatitis epidemic a focus of EASL Congress 2023

Tuesday 30th May, 2023 (Geneva, Switzerland)—The use of Artificial Intelligence (AI) to potentially measure the survival rates of liver cancer patients will feature in the scientific programme of the [EASL Congress 2023](#) to be held June 21-24 at the [Messe Wien Exhibition and Congress Centre](#) in Vienna, Austria.

The enormous medical potential of AI to transform disease prediction and detection has been gathering pace over the past six months and the technology’s future impact on liver disease is being widely discussed by hepatologists over the world. A special symposium, *Artificial intelligence in hepatology: Science Fiction or Science Fact?* will consider the latest developments in the field and a series of poster discussions around AI’s potential as a liver disease biomarker will be delivered at the event.

The congress is convened annually by the European Association for the Study of the Liver (EASL) and is expected to attract some 8,000 researchers, doctors, policy makers, industry leaders and affected communities from some 120 countries. For registered delegates unable to attend the in-person event, key sessions will be available online. All official onsite press conferences will also be broadcast live via Zoom.

Vienna is often considered as a city that bridges between East and West Europe and the impact of the Russian invasion of Ukraine is being felt across the continent. Tatiana Deshko, Director of Programs at the Alliance for Public Health Ukraine will deliver a keynote speech at the Opening Ceremony and describe the impact that the war is having on the delivery and maintenance of hepatitis and health services across the country.

Other highlights include Phase III trial results of a new drug to treat people living with fatty liver disease, the fastest growing disease in the world [affecting 1 in 3 people](#). NAFLD is already the fastest growing cause of hepatocellular carcinoma (HCC), the commonest form of liver cancer in the USA, France and the UK. If left unchecked, the annual predicted cost of NAFLD in Europe is

estimated to be greater than [€35 billion in direct costs to the health system, and a further €200 billion by way of wider costs to society.](#)

The trial results come at time when a new range of obesity drugs are attracting widespread media attention.

Another key study expected to make news is a randomised trial using faecal microbiota transplants to treat advanced cirrhosis advancing a growing interest in the relationship between gut health and the liver.

ENDS

Further information

Media Registration: Accredited media can apply for free registration [here](#)

Programme: For updates to the congress programme see [here](#)

Press Programme: All EASL Congress 2023 Official Press Conferences held onsite will also be broadcast live on Zoom for registered media.

Embargo Policy: Media representatives are asked to familiarise themselves with the official policy [EASL Congress 2023 Embargo Policy](#)

Further Information:

Michael Kessler
Michael Kessler Media
EASL Media Relations
Email: michael.kessler@intonon-media.com
Mob: +34 655 792 699
Twitter: @mickessler

About EASL Congress 2023

EASL Congress (previously known as the International Liver Congress) is EASL's flagship event, attracting scientific and medical experts from around the world to learn about the latest in liver research and exchange clinical experience. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice.

About [The European Association for the Study of the Liver \(EASL\)](#)

Since its foundation in 1966, this not-for-profit organisation has grown to over 5,200 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European association with international influence, and with an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policy.